TABLE 2.

Patient outcomes post–Haplo-BMT

Metric	Data (n = 23)
Median TNC dose	9.8 × 108 (5.9 to 11.7 × 108)
Median CD34 dose	4.7 × 106 (3 to 6 × 106)
Median time to neutrophil engraftment (days)	17
Median time to platelet engraftment (days)	32.5
Incidence of acute graft-versus-host disease	Skin—Grade III-IV—4.3% (1/23) GI —Grade II-IV—8.7% (2/23)
Incidence of chronic graft-versus-host disease	Mild/moderate—21.7% (5/23) Severe—4.3% (1/23)
Graft failure rate	Secondary—4.3% (1/23) day + 604 post transplant (with return of autologous hematopoiesis)
Donor chimerism at 6 months and 1 year	Whole blood B and T cell > 95%
Sickle cell disease-related symptoms post transplant	None in engrafted patients
Number of patients off immune suppression therapy at 12 months	86% (18/21)

Abbreviations: haplo-BMT, Haploidentical bone marrow transplant; PTLD, post-transplant lymphoproliferative disorder; TNC, target nucleated cell.